|Bid||88.23 x 800|
|Ask||88.28 x 1300|
|Day's range||87.93 - 88.42|
|52-week range||77.04 - 98.52|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||25.09|
|Forward dividend & yield||3.20 (3.61%)|
|1y target est||104.67|
Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.
Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.
The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.